ZNTL · CIK 0001725160 · operating
Based in San Diego, California, Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule cancer therapeutics. The company's primary focus is azenosertib, a checkpoint kinase inhibitor currently in Phase 3 clinical testing for ovarian cancer and additional solid tumor indications. This program represents the company's most advanced asset, with ongoing evaluation in both treatment-naïve and PARP-inhibitor resistant patient populations through the MAMMOTH trial and other clinical studies.
The company's pipeline also includes ZN-c3-001, evaluated in Phase 1 testing for azenosertib monotherapy across solid tumors. Zentalis maintains a licensing agreement and strategic collaboration with Recurium IP Holdings, LLC related to its development programs. As a clinical-stage entity, the company does not currently generate product revenues and operates through research and development activities and collaborations.
The organization operates with approximately 166 full-time employees and maintains operations in the United States. Zentalis was incorporated in 2014 and trades on the Nasdaq under the ticker ZNTL. The company's market capitalization is approximately $200 million.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.33 | $-2.33 | +47.9% | |
| 2023 | $-4.47 | $-4.47 | +0.2% | |
| 2022 | $-4.48 | $-4.48 | -303.6% | |
| 2021 | $-1.11 | $-1.11 | — | |
| 2020 | — | — | — |